Integrating anamnestic and lifestyle data with sphingolipid levels for risk-based prostate cancer screening
Authors:
- Caterina Peraldo-NeiaCPCaterina Peraldo-Neia
- Paola OstanoPOPaola Ostano
- Melissa SavioliMSMelissa Savioli
- Maurizia Mello-GrandMMMaurizia Mello-Grand
- Ilaria GregnaninIGIlaria Gregnanin
- Francesca GuanaFGFrancesca Guana
- Francesca CrivelliFCFrancesca Crivelli
- Michele Dei-CasMDMichele Dei-Cas
- Rita ParoniRita Paroni
Preprint
Abstract
Background: In the era of risk-based prostate cancer (PCa) screening, overcoming the limitations of prostate-specific antigen (PSA) testing and stratifying men by individual risk is crucial. Our study aims to integrate anamnestic and lifestyle data with circulating biomarkers to minimize unnecessary second-level investigations (SLIs) for patients with suspected PCa, while improving the detection of clinically significant PCa (ISUP>1). Methods: We collected plasma samples, recent clinical history, family cancer history, PSA levels, and lifestyle information from 904 men: 421 undergoing PSA testing, 421 with suspected and 62 with confirmed PCa. Univariable logistic regression was applied to identify ananmestic and lifestyle variables mostly associated with PCa. Penalized logistic regression models predictive of PCa or ISUP>1 PCa were built both using the 814 subjects with complete information for such variables, applying a 10-fold cross validation approach, and dividing the dataset into a training (n=445: 132 PCa, 313 non-PCa) and a test (n=369: 147 PCa, 222 non-PCa) set. The concentration of 50 sphingolipids was analysed on the latter set of 369 subjects by mass-spectrometry, and multivariable penalized regression with 10-fold cross-validation was applied to integrate anamnestic, lifestyle, sphingolipid data. ROC-AUCs on the test sets were compared with PSA ROC-AUCs. Results: Age, cardiovascular disease (CVD), number of medications, and sedentariness were significantly associated with PCa detection and their combination with PSA improved its performance (ROC-AUC from 0.85 to 0.89). In the SLI subgroup (n=437), adding age improved PSA predictive power (ROC-AUC from 0.60 to 0.70), but performance was still poor. Penalized regression with 10-fold cross-validation on the sphingolipid dataset identified hypertension, CVD, PSA, age, and five sphingolipids (HexCer-20, Cer-20, HexCer-24.1, GM3-24.1, DHCer-24) as key variables for accurate PCa classification (average ROC-AUC: 0.92). Cer-20 and CVD were consistently selected by models predicting ISUP>1 PCa. In the SLI subgroup, PSA, age, CVD, SM-16, HexCer-20, HexCer-24.1, DHS1P, and DHCer-24 were selected in all 10 models (average ROC-AUC: 0.83). Conclusions: Circulating sphingolipids are promising biomarkers that, when combined with PSA, anamnestic, and lifestyle data, may enhance PCa screening precision and reduce the need for invasive, costly examinations.Keywords
All Related Versions
- Published version: Journal of Translational Medicine, 23 (1), 1.
This publication has 29 references indexed in Scilit:
- Risk-stratified Approach to Implementing Population-based Prostate Cancer Screening in Five Pilot Sites in the European Union: A Protocol for the PRAISE-U ProjectEuropean Urology Open Science, 2024
- Comparing the Performance of Digital Rectal Examination and Prostate-specific Antigen as a Screening Test for Prostate Cancer: A Systematic Review and Meta-analysisEuropean Urology Oncology, 2024
- PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancerProstate Cancer and Prostatic Diseases, 2023
- The central role of Sphingosine kinase 1 in the development of neuroendocrine prostate cancer (NEPC): A new targeted therapy of NEPCClinical and Translational Medicine, 2022
- Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinaseEBioMedicine, 2021
- Head-to-head Comparison of Conventional, and Image- and Biomarker-based Prostate Cancer Risk CalculatorsEuropean Urology Focus, 2021
- Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancerProstate Cancer and Prostatic Diseases, 2021
- Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancerCochrane Database of Systematic Reviews, 2019
- Patterns in metabolite profile are associated with risk of more aggressive prostate cancer: A prospective study of 3,057 matched case–control sets from EPICInternational Journal of Cancer, 2019
- Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS BiopsyEuropean Urology Oncology, 2018